Rezolute/$RZLT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Rezolute
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.
Ticker
$RZLT
Sector
Primary listing
Employees
68
Headquarters
Website
Rezolute Metrics
BasicAdvanced
$669M
-
-$1.11
1.04
-
Price and volume
Market cap
$669M
Beta
1.04
52-week high
$8.34
52-week low
$2.22
Average daily volume
765K
Financial strength
Current ratio
8.429
Quick ratio
8.254
Long term debt to equity
1.405
Total debt to equity
2.15
Profitability
EBITDA (TTM)
-77.116
Management effectiveness
Return on assets (TTM)
-52.85%
Return on equity (TTM)
-95.15%
Valuation
Price to book
5.64
Price to tangible book (TTM)
5.64
Price to free cash flow (TTM)
-7.676
Free cash flow yield (TTM)
-13.03%
Free cash flow per share (TTM)
-1.002
Growth
Earnings per share change (TTM)
-1.83%
3-year earnings per share growth (CAGR)
-28.70%
10-year earnings per share growth (CAGR)
-27.24%
What the Analysts think about Rezolute
Analyst ratings (Buy, Hold, Sell) for Rezolute stock.
Bulls say / Bears say
U.S. Health Secretary’s initiatives to fast-track approvals for rare disease drugs may speed up Rezolute’s regulatory process and strengthen its position in hyperinsulinism therapies (Reuters).
Rezolute received Breakthrough Therapy Designation from the FDA for ersodetug in congenital hyperinsulinism on January 7, 2025, highlighting its strong clinical potential and accelerating development (NASDAQ).
The company’s April 2025 underwritten offering raised $96.9 million, extending its cash runway to mid-2027 and alleviating near-term financing pressure on its late-stage pipeline (Quiver Quantitative).
Rezolute’s net loss increased to $18.9 million in Q3 FY2025 from $17.1 million year-over-year, and cash and equivalents dropped to $88.4 million, indicating rising operating costs that pressure its financial runway (NASDAQ).
As of March 31, 2025, Rezolute accumulated net losses of $379.5 million and had just $14.6 million in cash, depending mostly on short-term debt securities and regular equity offerings to fund its clinical programs (SEC).
Both Phase 3 studies for ersodetug and RZ402 are still ongoing, with topline results not expected until December 2025 for congenital HI and the second half of 2026 for tumor HI, exposing shareholders to prolonged development and regulatory uncertainty (GlobeNewswire).
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.
Rezolute Financial Performance
Revenues and expenses
Rezolute Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Rezolute stock?
Rezolute (RZLT) has a market cap of $669M as of September 15, 2025.
What is the P/E ratio for Rezolute stock?
The price to earnings (P/E) ratio for Rezolute (RZLT) stock is 0 as of September 15, 2025.
Does Rezolute stock pay dividends?
No, Rezolute (RZLT) stock does not pay dividends to its shareholders as of September 15, 2025.
When is the next Rezolute dividend payment date?
Rezolute (RZLT) stock does not pay dividends to its shareholders.
What is the beta indicator for Rezolute?
Rezolute (RZLT) has a beta rating of 1.04. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.